Funding momentum Clinomic has secured a substantial Series B of €23 million ($25.4M) in 2025, signaling growing investor confidence and capital runway to scale its AI-driven hospital solutions. This suggests a window for upsell of expanded modules, implementation services, and enterprise-grade support.

Telemedicine expansion The launch of Mona Mobile indicates a strategic push into connected care and telemedicine for intensive and acute settings. This presents cross-sell opportunities for remote monitoring, AI triage features, and clinician workflow integration across hospitals adopting Mona Mobile.

AI hospital enablement Clinomic’s focus on intelligent, resource-driven digital transformation aligns with demand for AI-powered decision support, bed management, and ICU optimization. Target opportunities include expanding AI-driven workflows, data analytics dashboards, and interoperability with existing hospital IT ecosystems.

Growth potential With a global growth trajectory and a German based operation, Clinomic sits in a market with peers having higher headcount and revenue ranges. Partnering opportunities exist for joint go-to-market, white-labeling, or reseller arrangements to accelerate market penetration in Europe and beyond.

Strategic partnerships Clinomic’s pedigree as a spin-off from RWTH Aachen and its recognition in EIT Health Headstart showcases credibility for collaboration with healthcare providers, academic partners, and health-tech ecosystems. Leverage these connections to unlock co-development deals, pilot programs, or grant-funded deployments.